**Core tip:** Portal biliopathy in patients with portal vein thrombosis and portal cavernoma can be symptomatic in about 5%-38% of patients. Therapy includes endoscopic and surgical approaches aimed to improve both portal hypertension and biliary alterations and clinical manifestation. Usually, multiple and combined treatments are required to resolve portal biliopathy.

INTRODUCTION
============

Portal biliopathy (PB) is a clinical condition defined as the presence of abnormalities in the biliary tree (including biliary tree and gallbladder) in patients with non-cirrhotic/non-neoplastic extrahepatic portal vein obstruction (EHPVO) and portal cavernoma (PC)\[[@B1]\]. In literature, this disease has been named as "portal hypertensive biliopathy"\[[@B2]\], "portal cavernoma-associated cholangiopathy"\[[@B3]\], "portal cavernomacholangiopathy"\[[@B4]\], "cholangiopathy associated with portal hypertension"\[[@B5]\], "pseudosclerosing cholangitis"\[[@B6]\] and "pseudocholangiocarcinoma"\[[@B7]\] due to the fact that PB biliary alterations can mimic sclerosing cholangitis or cholangiocarcinoma, respectively.

The spectrum of biliary abnormalities shown at magnetic resonance cholangiopancreatography (MRCP) includes intra- and extra-hepatic biliary stenosis (single or multiple), with or without consensual above dilation; bile duct wall irregularity or thickening; bile duct angulation, varicose veins located at the ductular walls and gallbladder\[[@B3],[@B8]\].

The aim of this paper is to analyse PB clinical approaches based on classification and characteristics of portal biliopathy through a systematic review of the literature.

For this purpose, a systematic search on MEDLINE was conducted spanning April 1990 to April 2016. Studies were identified using the following terms: "portal biliopathy" OR "portal cholangiopahty" OR "pseudosclerosing cholangitis" OR "pseudocholangiocarcinoma" AND "treatment". In addition, all study references were consulted to identify any other relevant studies. Only studies on humans were considered, and only papers wrote in English were used for the analysis. Inclusion criteria were as follows: patients with PB secondary to non-neoplastic non-cirrhotic portal vein thrombosis (PVT) reporting endoscopic and surgical treatment of PB, both case series and case reports. Exclusion criteria were: review articles, guidelines or comment to other papers; iatrogenic PVT articles; papers about treatment of PB therapy complications or PB medical therapy; papers about PVT treatment.

A total of 118 articles were initially retrieved. Of these, 69 were excluded according to inclusion/exclusion criteria and the remaining 49 papers were included in this review (Figure [1](#F1){ref-type="fig"}).

![Flow-chart of literature search. PB: Portal biliopathy; PVT: Portal vein thrombosis.](WJG-22-9909-g001){#F1}

PATHOGENESIS
============

The development of PB in PC is due to two main mechanisms: a mechanical compression *ab extrinseco* of bile ducts (mainly hepatic biliary duct and common bile duct) by both the PC and the numerous compensatory collateral vein circles that arise after EHPVO formation, and an ischemic damage secondary to the altered vascularization due to EHPVO and PC.

Normally, venous drain of biliary tree is serviced by epicholedochal venous plexus of Saint and the paracholedochal plexus of Petren, whom normally diameter does not exceed 1 mm. In chronic portal vein obstruction these plexus are dilated in response to portal hypertension leading to thickening of biliary duct walls and compression, often with a characteristic radiological/endoscopic image of virtual lumen\[[@B9]-[@B11]\]. In particular, dilation of plexus of Saint causes fine irregularities in biliary walls while dilation of plexus of Petren causes extrinsic compression.

The ischemic damage seems to be related to deficient portal blood supply of the biliary tree secondary to EHPVO and PC and to thrombosis of small bile duct venules, resulting in strictures formation and fibrous\[[@B9]\].

The prevalence of biliary strictures due to a mechanical compression is about 55% among patients with PB, on the contrary in 45% of cases there was no relationship between stenosis localization and severity and cavernoma/collateral vein compression, suggesting the preponderance of ischemic damage in these cases\[[@B12]\]. However, both mechanisms can contribute at the same time in PB pathogenesis.

The bile stasis secondary to biliary strictures and hypothetic changes in bile compositions (increased pigment load due to hypersplenism, abnormal enterohepatic circulation of bile acids due to portal hypertension) can contribute to stones formation\[[@B13]\].

DIAGNOSIS AND CLASSIFICATION
============================

The diagnosis of PB is based on radiological imaging, in particular on cholangiography. MRCP is a non-invasive imaging test that can give a definite outline of biliary ductal abnormalities, and for these reasons it represents the modality of choice for PB diagnosis and evaluation. As previously mentioned, the main alterations evidenced at MRCP are bile duct stenosis, angulations and dilations, both intra and extra-hepatic, parietal irregularities, bile duct angulations, choledochal varices, lithiasis\[[@B3],[@B9]\]. Condat et al\[[@B3]\] purposed the use of MRCP coupled with magnetic resonance (MR) portography in the initial evaluation of PB, to assess both biliary abnormalities and portal anatomy, which helps in choice of the best therapeutic approach.

Initially, endoscopic retrograde cholangiopancreatography (ERCP) has been for many years the modality of choice to obtain cholangiographic images. Nowadays it has been replaced by MRCP in biliary diagnostic: ERCP is an invasive tool with possible complications, and it has only a therapeutic rather than diagnostic role. ERCP abnormalities are the same demonstrated at MRCP, however some old studies that used ERCP for PB diagnosis described a more frequent and severe left hepatic duct involvement (40%-100%) respect right hepatic duct (40%-57%)\[[@B6],[@B14]\].

Endoscopic ultrasound (EUS) has a complementary role and can evaluate biliary stenosis and dilations, stones, and in particular it is able demonstrate dilated peri-choledochal venous collateral vessels\[[@B15]\].

Abdominal ultrasound (US) has not a primary role in PB diagnosis but can be complementary to other techniques to evaluate presence and characteristics of PC, presence of gallbladder varices, signs of portal hypertension, gallstones, biliary tree dilation.

In the literature many classification have been published. Firstly, Chandra and Sarin\[[@B10]\] identified four PB types according with the biliary abnormalities localization at ERCP: type I, involvement of extrahepatic bile duct only; type II, involvement of intrahepatic bile duct only; type IIIa, involvement of extrahepatic bile duct and unilateral intrahepatic bile duct (left or right); type IIIb, involvement of extrahepatic bile duct and bilateral intrahepatic ducts. Llop et al\[[@B1]\] classified PB into different degrees of severity: grade I, biliary tree irregularities or angulations; grade II, indentations or strictures without dilation; grade III, strictures with dilation (defined as intrahepatic duct ≥ 4 mm or extrahepatic duct ≥ 7 mm).

At least, Shin et al\[[@B16]\] distinguished three type of PB base on pathogenetic mechanism: they described a varicoid type in which biliary irregularities are mainly caused by extrinsic compression, a fibrotic type in which strictures are due to fibrosis and wall thickening that results from ischemic injury, and a mixed type (both kind of alterations and pathogenetic mechanisms are involved).

CLINICAL MANIFESTATIONS AND NATURAL HISTORY
===========================================

Biliary changes are present in about 77%-100% of patients with PC\[[@B1],[@B3],[@B6]\]; however, only 5%-38% of patients developed biliary symptoms\[[@B1],[@B3],[@B14]\]. Symptoms and clinical manifestations of PB can be related to chronic cholestasis and/or biliary stones formations, and they include jaundice, cholangitis, cholecystitis, abdominal pain, cholelithiasis\[[@B17]\].

Risk factors for symptoms occurrence in PB are older age, longer duration of disease, common bile duct and gallbladder stones, and abnormal liver function tests (LFTs)\[[@B18]\].

The natural history of PB is still undefined. Dhiman et al\[[@B11]\] identified four stages in PB progression, shown in Table [1](#T1){ref-type="table"}. The progression from stage I to IV is due to worsening of biliary changes, symptoms onset, alterations in liver function tests and complications occurrence. Only one study by Llop et al\[[@B1]\] investigated the evolution of biliary changes and symptoms in patients with acute and chronic non-cirrhotic non-tumoral PVT: 67 patients were followed with MR angiography (MRA) and MRCP after PVT diagnosis. Among 22 patients with acute PVT, 73% developed biliary alterations at MRA/MR cholangiography (MRC) within a median follow-up of 33 mo (range 1-102): 4 patients had grade I PB, 4 grade II and 8 grade III, while 6 patient didn't had PB. In 14 patients without grade III PB, 11 performed another MR during a 43 mo follow-up and no progression to grade III PB was observed. Chronic PVT was present in 45 patients: within a median follow-up of 67 mo (range 0-749), 80% developed PB (3 patients grade I, 7 grade II and 26 grade III). Also in this group, no evolution from grade I-II PB to grade III PB was observed after a mean follow-up of 37 mo. Biliary symptoms occurred in 41% of grade III PB patients, while patients with grade I-II PB remained asymptomatic during follow-up \[Positive predictive value (PPV) 41%, Negative predictive value (NPV) 100%\]. In conclusion, when PB is established due to the formation of PC in EHPVO, the clinical picture will not change much over time and clinical manifestations will be mainly correlate with site and type of stenosis.

###### 

Characteristics of four stages in portal biliopathy natural history

  **Stage**      **Portal cavernoma**   **Biliopathy**     **LFTs**             **Symptoms**   **Complications**
  -------------- ---------------------- ------------------ -------------------- -------------- -------------------
  Preclinic      Yes                    No                 Normal               No             No
  Asymptomatic   Yes                    Early changes      Normal or abnormal   No             No
  Symptomatic    Yes                    Advanced changes   Abnormal             Yes            No
  Complicated    Yes                    Advanced changes   Abnormal             Yes            Yes

LFTs: Liver function tests.

THERAPEUTIC APPROACHES
======================

Treatment of PB is recommended only for symptomatic patients, whereas the presence of biliary abnormalities associated with mild biochemical alterations without clinical manifestations is not an indication for therapeutic intervention but requires a biochemical and clinical follow-up\[[@B11]\].

Therapy of portal biliopathy should be addressed to firstly reduce portal hypertension and secondly to resolve biliary obstruction. Both surgical and radiological porto-systemic shunt (PSS) can be considered the treatment of choice to reduce portal hypertension in patients with EHPVO and PC; when PB is related only to a mechanical compression, this approach can resolve both PC and PB at the same time\[[@B19]\]. However, when the damage of the biliary tree is also ischemic, portal decompression alone is not sufficient to relief biliary obstruction, and in many cases patients need multiple endoscopic and surgical interventions on biliary tree during their life. An example of cholangiographic findings at ERCP before and after endoscopic plastic stent placement is shown in Figure [2](#F2){ref-type="fig"}.

![Cholangiographic findings in a patient with symptomatic (jaundice and cholangitis) portal biliopathy secondary to chronic extrahepatic portal vein obstruction and portal cavernoma. Ischemic stenosis with dilatation of the left intrahepatic biliary tree is shown by ERCP (A): patient underwent unsuccessful ERCP with stent insertion and then PTBD placement; PTBD was changed for 3 times in one year because of cholangitis and liver abscess. After clinical and biochemical improvement of BA, patient was treated with surgical splenorenal shunt and after 5 mo PTBD was definitively removed. Last cholangiography obtained before PTBD removal shows significant improvement in biliary dilation (B). Patient is actually asymptomatic for BA and PB management. BA: Bilioenteric anastomosis; ERCP: Endoscopic retrograde cholangiopancreatography; PB: Portal biliopathy; PTBD: Percutaneous transhepatic biliary drainage.](WJG-22-9909-g002){#F2}

Medical treatment with ursodeoxycholic acid (UDCA) has a limited role, even if some authors reported resolution or improvement of mild PB symptoms (mainly abdominal pain and biochemical cholestasis without evidence of stones) and prevention in recurrence of cholangitis after UDCA therapy alone\[[@B1],[@B17],[@B20]\].

At the moment, there is not a standardized flow-chart for PB therapy, and data about different and combined approaches and their outcomes are reported from small series and case reports.

Considering all papers included in this review, a total of 284 PB patients were described, among these, the most frequent described symptoms were jaundice (52.8%), cholangitis (27.1%) and abdominal pain (19.4%). The mean age at PB presentation was 33.5 ± 13.5.

Hereafter we analyze the different types of treatment reported in the included articles.

Endoscopic treatment
--------------------

Among the total of symptomatic PB patients included in case series and case reports, 114 patients were treat endoscopically at first. Only in 34 patients (29.8%) a single endoscopic treatment resolved PB alterations and symptoms; among these, 13 patients had common bile duct (CBD) stones as PB manifestation resolved after endoscopic sphincterotomy (ES) + stone extraction (SE). In most cases, repeated treatment were necessary to have a complete resolution of biliary abnormalities, often combined with surgical intervention for portal hypertension: after the first treatment, 49 patients (43%) underwent multiple plastic stent exchange, 4 (3.5%) metallic stent placement, 35 (30.7%) surgical treatment with PSS or splenectomy (with or without esophageal devascularisation), 7 (6%) surgical biliary anastomosis, 2 (1.7%) transjugular intrahepatic porto-systemic shunt (TIPS) and 1 (0.9%) liver transplantation (LT). The duration of follow-up, when reported, range between 2 d and 18 years. In these cases the endoscopic approach can be considered safe, even if some complications have been reported. The most frequent is haemobilia, occurred in 24 procedures (in one case after intracholedocal biopsy). The risk of haemobilia during endoscopic treatment for PB is related to the presence of numerous pericholedocal compensatory collateral veins and congestion of biliary duct walls vessels. In particular, the transient pressure elevation in the distal portion of biliary varices during balloon sweeping can increase the risk of bleeding\[[@B21]\]. For these reasons, a decompressive shunting procedure performed before endoscopic treatment could reduce the risk of haemobilia\[[@B21],[@B22]\].

Cholangitis were also frequent (reported after 53 procedures), but although they can be seen after ERCP in up to 15.4% of cases\[[@B23]\], they are often not directly related to the endoscopic treatment but rather to recurrence of sludge or stones inside the biliary stent and can be treated with stent exchange. Sepsis was observed as well in 3 cases. Mortality directly related to endoscopic treatment was 0%, but one patient died for secondary biliary cirrhosis and one for cholangitis, both developed despite multiple stent placements during the treatment period.

The choice of the endoscopic treatment of PB depends on the type of biliary alterations and includes ERCP with ES, SE (with previous mechanical lithotripsy if necessary) for patients with choledocholithiasis, stricture dilation ± biliary stent or nasobiliary drain placement.

The largest series of PB patients endoscopically treated is described by Saraswat et al\[[@B24]\], who published data about 130 ERCP performed for biliary strictures in 20 symptomatic patients. ES with SE was performed in 8 patients with choledochal stones and 9 patients were treated with plastic stents placement. Eleven patients (for a total of 101 procedures) were treated on the line of postoperative benign biliary strictures, with balloon dilation and plastic stent insertion, that were exchanged every 3-4 mo until LFTs normalizations; in 8/11 case a cholangiogram normalization was achieved as well. ERCP complications included haemobilia in 9/130 procedures and cholangitis in 40/130 (mainly already present at the moment of ERCP and due to delay in stent exchanged).

Khare et al\[[@B25]\] published a case series including 13 patients with EHPVO and PC complicated by symptomatic PB divided in 3 groups according to radiological biliary findings: group A included 5 patients with biliary strictures without choledocholithiasis; group B included 3 patients with choledocholithiasis alone; group C included 5 patients with both biliary strictures and choledocholithiasis. In group A, 4 patients were treated endoscopically with biliary stenting alone (n. 3) or with previous dilation (n. 1), followed by surgical PSS for portal hypertension. In 3/4 patients ERCP resolved biliary strictures, while 1 patient showed persistent stenosis at 12 mo and underwent multiple endoscopic procedures with dilation and stenting. In group B, 2/3 patients were treated with endoscopic SE that was successful in one patient; the other patient underwent stent placement and then surgical intervention for portal hypertension (splenectomy with esophagogastric devascularisation). During the follow-up, this patient needed multiple ERCP for choledochus clearance. In group C, four patients were first treated with endoscopic approach but SE failed in all of these patients; after surgical approaches (PSS or splenectomy with esophagogastric devascularisation), 2/4 patients were successfully managed with repeated ERCP with dilation and SE. No complications were observed after ERCP.

In 2009 the group from Birmingham published his experience with 13 patients with symptomatic portal biliopathy\[[@B17]\]: at the cholangiography (PB was diagnosed with MRC in 12 patients and with ERCP in 1), 12 patients showed biliary strictures, 10 bile duct stones/sludge, 11 gallbladder stones/sludge. In one patients symptoms (right hypocondrial pain and dark urine) resolved spontaneously, while 12 patients underwent therapeutic ERCP that was successful in 8: in one patients with associated Crohn's disease plastic stent insertion did not resolved jaundice and the patient, that was not eligible for surgical portal decompression for PVT extension, was listened for liver and small bowel transplantation; one patient had an excellent response to ES and SE. Among 7 patients with jaundice resolution after plastic stent insertion, 2 patients underwent portal decompression for recurrent cholangitis despite multiple ERCP (one with PSS and one with TIPS), 1 needed repeated plastic stent changes and in 3 patients a metallic biliary stent was placed after several repeat plastic stent changes. Among 4 cases in which ERCP was unsuccessful, 2 had spontaneous resolution. The observed complications during a total of 49 ERCP were haemobilia (4%) and sepsis (6%, two cholangitis and one enterococcal sepsis), and no death directly related to biliary complications was observed during the follow-up.

In particular, the last two articles evidence how complex is to choice the appropriate treatment for PB, and the great variability on patients response to the same therapy, even between patients with the same type of biliary manifestation. This is also due to the difficulty to classify the etiology of PB (varicoid type or fibrotic type) based on cholangiographic findings.

Combined treatment with biliary procedures and percutaneous transhepatic portal vein recanalization (balloon dilation + self-expandable stent placement) have also been reported\[[@B26]\].

The role of UDCA administration associated with endoscopic procedures is still uncertain: even if some authors reported the absence of biliary symptoms recurrence after endoscopic treatment associated with UDCA therapy\[[@B1],[@B3]\], equally good results with the only endoscopic management are reported.

All published PB case series and case reports about endoscopic treatment of PB are summarized in Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}\[[@B1],[@B3],[@B15],[@B17],[@B20],[@B22]-[@B47]\], respectively.

###### 

Endoscopic management of portal biliopathy: summary of case series

  **Ref**.                            **No. of patients**            **Biliary abnormalities**                                          **First treatment**                                                           **Follow-up**             **Further treatments**                                              **Complications/outcome**
  ----------------------------------- ------------------------------ ------------------------------------------------------------------ ----------------------------------------------------------------------------- ------------------------- ------------------------------------------------------------------- ------------------------------------------------
  Bhatia et al\[[@B27]\], 1995        4 symptomatic                  Stenosis + stones 3 CBD stones 4                                   ES + SE + NBD 4                                                               3-8 mo                    Multiple ERCP 4                                                     None
  Perlemuter et al\[[@B20]\], 1996    8 symptomatic                  Stenosis 8 CBD stones 2 Cholangitis 1                              ES+NBD 3 BD 1 PSS 1 UDCA 2                                                    6-60 mo                   Multiple ES 1                                                       Death 2 (cholangitis 1; stroke 1)
  Condat et al\[[@B3]\], 2003         7 symptomatic                  Cholecystitis/right hypocondrial pain 4 Cholangitis 1 Stenosis 2   Cholecystostomy + SE 1 Stent 1 BA + PTBD 1 UDCA 4                             4-25 mo                   \-                                                                  Haemobilia 1
  Sezgin et al\[[@B28]\], 2003        10 symptomatic                 Stenosis 9 IE stones 1                                             ES + stent 10 NBD 4 BD 4                                                      3.3 yr (range 1-7)        Multiple ERCP 5                                                     Haemobilia 1 Cholangitis 5 Death 1
  Dumortier et al\[[@B22]\], 2003     6 symptomatic                  Stenosis 5 CBD stones 2                                            ES 5 BD 5 SE 2 Stent 1                                                        10 mo (range 2 d-18 mo)   Multiple ERCP + PSS 4                                               Cholangitis 1 Cholecystitis 4
  Khare et al\[[@B25]\], 2005         13 symptomatic                 Stenosis 10 CBD stones 8                                           Stent 4 BD 6 SE 4                                                             \-                        PSS 8 BA 1 Multiple ERCP 2 Splenectomy + devasc 2                   Death 1
  Dhiman et al\[[@B29]\], 2007        12 symptomatic                 Stenosis 7 CBD stones 5 CBD varices 1 Mirizzi'ssdr 1               PSS 5 ES 3 ES + BD 2 Stent 4                                                  19 mo (6-132 mo)          Multiple ERCP in pts initially treated with stent                   Cholangitis in 2 pts treated with stent
  Vibert et al\[[@B30]\], 2007        19 symptomatic                 IE biliary dilation 9 IE stones 7 CBD stones 4                     PSS group: PTBD 1 SRS 10 NPSS group: ES + stent 2 ES + SE 1 PTBD 6 BA 4       19 pts 8.3 yr             PSS group: BA 5 NPSS group PTBD 1 after ERCP and 4 after BA         Resolution 17 Death 3
  Oo et al\[[@B17]\], 2009            13 symptomatic                 Stenosis 13 CBD stones 10 GB stones 11                             UDCA 1 Stent 7 ES + SE 1 Failed ERCP 4                                        2 yr (1-18 aa)            Metallic stent 3 Stent exchange 2 PSS 3 (2 TIPS, 1 surgical) LT 1   Haemobilia 2 Sepsis 3
  Llop et al\[[@B1]\], 2011           14 symptomatic                 Stenosis 14 CBD stones 6 GB stones 2                               ES + SE 6 ES + UDCA 2 Cholecystectomy 2                                       \-                        Multiple ERCP 1 BA 1                                                \-
  Saraswat et al\[[@B24]\], 2013      20 symptomatic                 Stenosis 20 CBD stones 8 GB stones 6                               ES + SE 8 Stent 9 BD + stent 11                                               18 mesi (range 3-188)     Multiple ERCP 11                                                    In 130 procedures: Cholangitis 40 Haemobilia 9
  Ramchandani et al\[[@B31]\], 2013   5 symptomatic                  CBD stenosis 2 CHD stenosis 1 CBD stones 2                         Metallic stent 1 Plastic stent 2 BD + stent 1 Intracholedocal lithotripsy 1   6-7 mo                    SRS 2 Stent Exchange 1                                              \- Resolution 5
  Cellich et al\[[@B23]\], 2015       8 symptomatic 1 asymptomatic   Stenosis 7 CBD stones 3 GB stones 1                                ES 7 BD 4 SE 2 Stent 7                                                        \-                        PSS 1 Stent exchange 3 BA 3                                         Cholangitis 3 Haemobilia 1

CBD: Common bile duct; GB: Gallbladder; IE: Intrahepatic; ES: Endoscopic sphincterotomy; SE: Stone extraction; NBD: Nasobiliary drainage; BD: Balloon dilation; PSS: Porto-systemic shunt; NPSS: No porto-systemic shunt; UDCA: Ursodeoxycholic acid; ERCP: Endoscopic retrograde cholangio-pancreatography; BA: Bilioenteric anastomosis; SRS: Splenorenal shunt; LT: Liver transplantation; TIPS: Transjugular intrahepatic porto-systemic shunt.

###### 

Endoscopic management of portal biliopathy: summary of case reports

  **Ref**.                                   **Patients**                 **Biliary abnormalities**                 **First treatment**                **Follow-up**   **Further treatment**                                                 **Complications**
  ------------------------------------------ ---------------------------- ----------------------------------------- ---------------------------------- --------------- --------------------------------------------------------------------- --------------------------
  Mörk et al\[[@B32]\], 1998                 2                            CBD stenosis 2                            Stent 2                            \-              Multiple Stent exchange + PSS 1                                       Cholangitis 1
  Solmi et al\[[@B33]\], 1998                1                            Stenosis                                  Stent                              \-              \-                                                                    \-
  Mutignani et al\[[@B34]\], 2002            3                            CBD stenosis 3                            Stent 3                            \-              PSS 3                                                                 Haemobilia 3
  Perego et al\[[@B35]\], 2003               1                            Stenosis + CBD stones                     \- Stent                           3 yr            Multiple stent exchange→PTBD + dilation and SE                        \-
  Umphress et al\[[@B15]\], 2004             M, 62 yr                     IE and CBD stones                         ES + SE + stent                    1 yr            Stent exchange and cholecistectomy                                    \-
  Guerrero Hernández et al\[[@B36]\], 2005   M, 29 yrs                    CBD stenosis                              ERBD + Sugiura                     \-              \-                                                                    \-
  Rosenthal et al\[[@B37]\], 2008            F, 44 yr                     CBD stenosis and stones                   Stent + SE                         \-              PSS                                                                   \-
  Ajayi et al\[[@B38]\], 2009                F, 13 yr                     Stenosis                                  ES + BD + stent                    6 mo            Multiple stent exchange                                               \-
  Layec et al\[[@B39]\], 2009                F, 74 yr                     Stenosis                                  Metallic stent                     18 mo           Metallic stent                                                        Haemobilia
  Sharma et al\[[@B40]\], 2009               M, 35 yr F, 30 yr M, 25 yr   CBD stenosis 3                            ES+SE 3                            \-              \-                                                                    Haemobilia 3
  Vasiliadis et al\[[@B41]\], 2009           F, 39 yr                     CBD stenosis                              ES                                 19 mo           Multiple stent exchange→PSS + cholecistectomy                         \-
  Cantù et al\[[@B42]\], 2010                M, 31 yr                     CBD stenosis                              ES + stent                         4 yr            \-                                                                    \-
  Martinez et al\[[@B43]\], 2011             M, 34 yr                     IE diltaions                              Stent                              \-              \-                                                                    \-
  Mistry et al\[[@B44]\], 2012               M, 28 yr                     CBD stenosis                              BD + BA + PTBD                     \-              Percutaneous transhepatic-gastrostomy                                 Haemobilia
  Alam et al\[[@B45]\], 2012                 M, 30 yr F, 19 yr            CBD stenosis 2 GB stones 1 CBD stones 1   PTBD Stent                         \-              Cholecistectomy                                                       \-
  D'Souza et al\[[@B46]\], 2013              M, 49 yr                     CBD stenosis                              Stent + BD (after stent removal)   \-              PSS + splenectomy                                                     Haemobilia (post-biopsy)
  Bernon et al\[[@B47]\], 2014               M, 36 yr                     CBD stenosis and stones                   SE + stent                         1 yr            Stent exchange→PTBD→cholecistectomy, intrahepatic 3 semgment bypass   Cholangitis
  Hyun et al\[[@B26]\], 2015                 M, 33 yr                     CBD stenosis                              ERBD→PTBD + portal stent           3 mo            \-                                                                    Haemobilia

CBD: Common bile duct; ES: Endoscopic sphincterotomy; SE: Stone extraction; BD: Balloon dilation; PSS: Porto-systemic shunt; IE: Intrahepatic; BA: Bilioenteric anastomosis; ERBD: Endoscopic retrograde biliary drainage; PTBD: Percutaneous transhepatic biliary drainage.

Surgical treatment
------------------

Indication to surgery in PB patients is given by the need to decompress the portal system through PSS and to resolve the biliary obstruction. In cases in which PB is due to biliary compression by PC, the detension of collateral vessels obtained with the reduction of portal pressure by PSS can resolve in the same time biliary obstruction\[[@B30]\]. The most common PSS performed are proximal spleno-renal shunt or mesocaval shunt, but other types of surgical shunts include meso-gonadal vein shunt, meso-renal shunt, right-porto ovarian shunt, shunt between a portal varix and cava\[[@B41],[@B48]-[@B51]\].

However, in patients without resolution of biliary abnormalities and symptoms after PSS, a second stage procedure can be required: biliary stenosis can be managed endoscopically, as explain above, or with surgical construction of a bilioenteric anastomosis. In patients without a suitable patent vein, splenectomy associated with esophagogastric devascularisation could reduce pressure in pericholedochal collateral veins and improve biliary symptoms\[[@B52]\]. A surgical approach with intrahepatic segment 3 bypass has been described to provide definitive treatment for biliary decompression and stone removal in a single time procedure in appropriately selected patients\[[@B47]\].

The largest PB series\[[@B52]\] retrospectively included 56 PB patients who underwent surgery from 1996 to 2010; 32/56 (57.1%) were asymptomatic for PB. To reduce portal hypertension, PSS was performed in 40 patients and splenectomy with devascularisation in 16. After first-line surgery, 7 patients required endoscopic treatment for cholangitis or CBD stones, that was successful in 2 patients, while 5 of them required multiple procedures; 2 patients previously treated with PSS at least needed biliary surgery for dominant CBD stricture that required frequent stent exchanges. In addition, the authors reported a significant reduction in serum biliary levels after first-line surgery (both shunt and no-shunt surgery) and alkaline phosphatases (shunt surgery), confirming that the resolution or improvement in portal hypertension can be effective in relieving biliary obstruction.

Vibert et al\[[@B30]\] published a case series including 19 symptomatic PB patients and propose an interesting 3 steps approach: (1) biliary drainage and antibiotic therapy if cholangitis is present; (2) surgical PSS; and (3) biliodigestive anastomosis with hepatico-jejunal anastomosis with Roux-en-Y. Patients were divided in two groups according to feasibility of PSS: 10 patients were included in the PSS group, 9 patients in the no PSS (NPSS) group. In the first group, one patient with severe sepsis from cholangitis underwent percutaneous transhepatic biliary drainage (PTBD) with extraction of intrahepatic stones. Then, a splenorenal shunt was performed in all 10 patients. Mortality was nil, and complications rate was 27%, including one chylus fistula and 2 early thrombosis, successfully treated with anticoagulant therapy or angiographic-guided pneumatic dilation. Initially, PSS was successful in biliary symptoms resolution in 70% of cases, but within 30 mo after PSS 5/10 patients required a bilioenteric anastomosis because of persistent jaundice or recurrent cholangitis. In the NPSS group, 3 patients were initially treated with endoscopic approach (1 ES and 2 plastic stent placement); PTBD was positioned in 6 patients (in 3 cases because of recurrence of biliary symptoms after endoscopic treatment); biliodigestive anastomosis was performed in 4 patients. Among these, one patient initially treated with endoscopic stent placement, 2 patients initially treated with PTBD and 4 patients treated with biliodigestive anastomosis needed repeated transhepatic cholangioscopies to remove intrahepatic stones and to improve biliary drainage; except for 2 patients lost in follow-up, at long-term follow-up one patient died for severe cholangitis and haemobilia while other patients were asymptomatic.

Overall, 173 patients underwent surgery intervention as first or second step for PB treatment: PSS was performed in 131 patients, PSS with splenectomy in 7, splenectomy with devascularisation in 18, devascularisation in 1 and 16 patients underwent biliary surgery (biliodigestive anastomosis, cholecystectomy, choledochotomy). The reported follow-up after surgical intervention ranged between 4 mo and 15 years. Considering patients underwent PSS alone as first treatment for PB, biliary symptoms relieve in 64.1% of cases, while in patients firstly treated with surgical biliary anastomosis, only in 30% of cases no other treatment was required.

A total of 6 death was reported: 1 patients died after 10 years from splenectomy for recurrence of gastrointestinal bleeding, 1 patient died for decompensated alcoholic cirrhosis, one for perforated duodenal ulcer and one for cholangitis and haemobilia after 8.6 years from biliodigestive anastomosis, 2 patients died for intraoperative bleeding during surgery on bile duct (choledocholithotomy and hepaticojejunostomy), suggesting a higher risk of bleeding from biliary tree due to the presence of numerous compensatory collateral veins and the congestion of biliary and splanchnic venous system. Table [4](#T4){ref-type="table"}\[[@B2],[@B3],[@B19],[@B25],[@B30],[@B51]-[@B58]\] summarized papers about surgical intervention in PB patients.

###### 

Surgical management of portal biliopathy: summary of case series and case reports

  **Ref**.                                 **No. of patients**              **Biliary abnormalities**                                                     **First treatment**                                                                          **Follow-up**                 **Further treatments**                                                                          **Complications/outcome**
  ---------------------------------------- -------------------------------- ----------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- ----------------------------- ----------------------------------------------------------------------------------------------- --------------------------------------------
  Chaudhary et al\[[@B53]\], 1998          9 symptomatic                    Stenosis: 2 CBD stones: 2                                                     BA 2 SRS 7                                                                                   9 pts -                       BA 2 Stent 1 ES + SE 2                                                                          Death 1 Resolution 7
  Condat et al\[[@B3]\], 2003              7 symptomatic                    Cholecystitis/right hypocondrial pain 4 Cholangitis 1 Stenosis 2              Cholecystostomy + ERCP 1 Stent 1 BA+PTBD 1                                                   4-25 mo                       \-                                                                                              Haemobilia 1
  Gauthier-Villars et al\[[@B19]\], 2005   8 symptomatic (pediatric)        Stenosis 6 Biliarydilation 8                                                  \- PSS 8                                                                                     8 pts 4.5-15 yr               \-                                                                                              Complete resolution 7 Partial resolution 1
  Khare et al\[[@B25]\], 2005              13 symptomatic                   A: Stenosis 5 B: CBD stones 3 C: Stenosis + CBD stones 5                      A: PSS 4; BA 1 B: ERCP 2; PSS + BA 1 C: Unsuccessful ERCP 4; PSS 3; Splenectomy + devasc 2   \-                            A: Multiple ERCP: 1 B: Splenectomy 1 (post-ERCP) C: Multiple ERCP 2; BA 1; Splenectomy + BA 1   Death 1
  Vibert et al\[[@B30]\], 2007             19 symptomatic                   IE biliary dilation 9 IE stones 7 CBD stones 4                                PSS group: PTBD 1 SRS 10 NPSS group: ES + stent 2 ES + SE 1 PTBD 6 BA 4                      19 pts 4-30 mo                PSS group: BA 5 NPSS group PTBD 1 after ERCP and 4 after BA                                     Resolution 17 Death 3
  Dhiman et al\[[@B2]\], 2007              12 symptomatic                   Stenosis: 7 CBD stones: 5 Choledochal varices 2 Mirizzi'ssyndrome 1           PSS 5 ES 3 ES + dilation 2 Stent 4                                                           19 mo (range 6-132)           Multiple stent exchange in pts initially treated with stent                                     Cholangitis in 2 pts treated with stent
  D'Souza et al\[[@B54]\], 2009            1 symptomatic                    CBD stenosis + GB stones                                                      Pre-surgery stent→PSS + BA (single stage)                                                    18 mo                         \-                                                                                              Resolution
  Camerlo et al\[[@B51]\], 2010            3 symptomatic                    Stenosis 3                                                                    PSS 3 Stent 1 (pre-PSS)                                                                      3 pts 2-13 yr                 \-                                                                                              Resolution 3
  Agarwal et al\[[@B55]\], 2011            39 symptomatic                   Stenosis 15 CBD stones 7 GB stones 12 IE dilation 39                          SRS 37 BA 2                                                                                  37 pts 32 mo                  ES ± SE 10 BA 12 ES + cholecystectomy 1                                                         Resolution 35
  Chattopadhyay et al\[[@B52]\], 2012      24 symptomatic 32 asymptomatic   CBD stenosis 3 Multiple stenosis 5 IE dilation 14 CBD stones 7 GB stones 11   ERCP pre-surgery 12 PSS 40 Splenectomy + devasc. 16                                          43 pts 48 mo (range 14-120)   ES + SE 2 Multiple ES + stent 5 BA 2                                                            Resolution 38 Death 1
  Suárez et al\[[@B56]\], 2013             3 symptomatic                    Stenosis 3                                                                    UDCA 1 BA 1                                                                                  \-                            \-                                                                                              \-
  Bhatia et al\[[@B57]\], 2014             2 symptomatic                    GB stones                                                                     Cholecistectomy                                                                              \-                            \-                                                                                              Resolution
  Liu et al\[[@B58]\], 2015                18                               Stenosis 6 Dilations 6 Stenosis + dilations 6                                 PSS 18                                                                                       \-                            \-                                                                                              Resolution 15

CBD: Common bile duct; GB: Gallbladder; IE: Intrahepatic; ES: Endoscopic sphincterotomy; SE: Stone extraction; BD: Balloon dilation; PSS: Porto-systemic shunt; NPSS: No porto-systemic shunt; UDCA: Ursodeoxycholic acid; ERCP: Endoscopic retrograde cholangio-pancreatography; BA: Bilioenteric anastomosis; SRS: Splenorenal shunt; FU: Follow-up.

TIPS
----

In addition to surgical PSS, a TIPS placement can be a valid alternative to improve portal hypertension. Since 1996, Görgül et al\[[@B59]\] observed the resolution of "pseudocholangiocarcinoma" sign after TIPS in 3 patients. In a case report, a 45-years-old woman affected by cholestatic jaundice due to compression on CBD by extrahepatic portal and splenic vein thrombosis with collateral, was treated with TIPS: in order to decompress the biliary tree before the procedure, a biliary stent was placed and the day after TIPS was successfully performed. The biliary stent was removed after 1 wk and, at 14 mo follow-up, the patient was asymptomatic and MR/MRCP showed a significant improvement of biliary alterations and of cavernoma size\[[@B60]\]. Another case report described resolution of cholangiographic CBD abnormalities and normalization of LFTs after TIPS performed in a patient with PB and portal hypertension secondary to PVT\[[@B61]\]. In the case series published by Cellich et al\[[@B23]\] including 13 PB patients, one of these was initially treated with TIPS that was unsuccessful; patient underwent PSS and multiple endoscopic treatment and, at least, bilioenteric anastomosis. Oo et al\[[@B17]\] reported 2 patients successfully treated with TIPS: one after repeated ERCP with plastic stent exchanges obtaining resolution of biliary symptoms and reduction in portal pressure; the second was successfully treated with temporary PTBD placement followed by TIPS. Even if the use of TIPS in PB patients is anecdotal, this technique seems effective and safe in treatment of portal hypertension and PB secondary to PC. However, due to the vascular alterations secondary to PC, TIPS is not always technically feasible.

LT
--

There are few data about LT for PB patients. In literature only 4 cases are reported (1 regarding a paediatric patient), 2 living donor LT and 2 deceased donor LT\[[@B62]-[@B65]\]. Indication for LT was secondary biliary cirrhosis, recurrent cholangitis (even with suspicion of cholangiocarcinoma) despite multiple endoscopic treatments, often associated with gastrointestinal bleeding\[[@B62]-[@B64]\]; Zhang et al\[[@B65]\] reported 3 successful living donor LT in 3 paediatric patients with PC, one of these with jaundice and evidence of dilated biliary duct due to PC compression, consistent with PB; however, in all 3 cases the major indication for LT was deteriorating liver function ad recurrent gastrointestinal bleeding. In all the 4 cases of LT for PB the outcome was favourable after a follow up of 12-26 mo.

CONCLUSION
==========

PB is a frequent complication in patients with chronic PVT and PC, however symptoms are present in a minority of cases and only symptomatic patients require therapy.

The majority of patients with PC and PB need multiple treatments during their life, aimed both to decompress portal circle and to resolve biliary abnormalities and symptoms; only few patients have a complete resolution of biliary and vascular problem after the first intervention, and it can be seen more often in PSS performed for PC compressing the bile duct. In most cases a combined approach is required (endoscopy and surgery), but a consensus on the timing and priority of treatments is not still available.

In Figure [3](#F3){ref-type="fig"} we propose a possible algorithm for the management of PB. For asymptomatic patients, no specific therapy is required except the eventual treatment of portal hypertension complications; during follow-up LFTs monitoring is suggested. For symptomatic patients, cholecistectomy is recommended in case of gallbladder stones or cholecistitis alone. In case of PB due to PC compression (varicoid type), surgical PSS or TIPS (when feasible) should resolve both PC and bleary stenosis. However, if cholangitis or choledoholitiasis are present, they should be treated at first. In case of mixed type, an ischemic damage coexist with the compressive one and the only PSS will not solve the problem; in these case, further interventions on the biliary system are needed: consider ES with/without stent placement and, in case of persistence of biliary symptoms despite multiple endoscopic treatments, surgical intervention of bilioenteric anastomosis. When a fibrotic type of PB is diagnosed, PSS will not resolve the biliary alterations. In these cases, PB resolution is difficult to achieve and multiple endoscopic/surgical biliary treatments are required. Patients can be evaluated for LT in case of secondary biliary cirrhosis, recurrent cholangitis despite multiple endoscopic treatments or difficult control in portal hypertension manifestations.

![Proposed algorithm for portal biliopathy management. ^1^Unsuccessful vascular surgery is frequent in mixed type because of co-presence of ischemic and compressive damage. ES: Endoscopic sphincterotomy; SE: Stone extraction; LFTs: Liver function tests; LT: Liver transplantation; PTBD: Percutaneous transhepatic biliary drainage; PB: Portal biliopathy; PSS: Porto-systemic shunt; TIPS: Transjugular intrahepatic porto-systemic shunt.](WJG-22-9909-g003){#F3}
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